Yost SE - Search Results

1

Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer.

Lee KM, Lin CC, Servetto A, Bae J, Kandagatla V, Ye D, Kim G, Sudhan DR, Mendiratta S, González Ericsson PI, Balko JM, Lee J, Barnes S, Malladi VS, Tabrizi S, Reddy SM, Yum S, Chang CW, Hutchinson KE, Yost SE, Yuan Y, Chen ZJ, Fu YX, Hanker AB, Arteaga CL. Lee KM, et al. Among authors: yost se. Cancer Immunol Res. 2022 Jul 1;10(7):829-843. doi: 10.1158/2326-6066.CIR-21-0826. Cancer Immunol Res. 2022. PMID: 35561311 Free PMC article.

2

Genomic mutation-driven metastatic breast cancer therapy: a single center experience.

Yuan Y, Yost SE, Yim J, Yuan YC, Solomon NM, Mambetsariev I, Pal S, Frankel P, Salgia R, Neuhausen SL, Mortimer J. Yuan Y, et al. Among authors: yost se. Oncotarget. 2017 Apr 18;8(16):26414-26423. doi: 10.18632/oncotarget.14476. Oncotarget. 2017. PMID: 28061482 Free PMC article.

3

CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.

Zhao ZM, Yost SE, Hutchinson KE, Li SM, Yuan YC, Noorbakhsh J, Liu Z, Warden C, Johnson RM, Wu X, Chuang JH, Yuan Y. Zhao ZM, et al. Among authors: yost se. BMC Cancer. 2019 Jan 21;19(1):96. doi: 10.1186/s12885-019-5290-4. BMC Cancer. 2019. PMID: 30665374 Free PMC article.

4

Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer.

Yuan Y, Wen W, Yost SE, Xing Q, Yan J, Han ES, Mortimer J, Yim JH. Yuan Y, et al. Among authors: yost se. Sci Rep. 2019 May 17;9(1):7509. doi: 10.1038/s41598-019-43429-7. Sci Rep. 2019. PMID: 31101835 Free PMC article.

5

Differential gene expression and AKT targeting in triple negative breast cancer.

Lin FM, Yost SE, Wen W, Frankel PH, Schmolze D, Chu PG, Yuan YC, Liu Z, Yim J, Chen Z, Yuan Y. Lin FM, et al. Among authors: yost se. Oncotarget. 2019 Jul 9;10(43):4356-4368. doi: 10.18632/oncotarget.27026. eCollection 2019 Jul 9. Oncotarget. 2019. PMID: 31320990 Free PMC article.

6

Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer.

Wen W, Marcinkowski E, Luyimbazi D, Luu T, Xing Q, Yan J, Wang Y, Wu J, Guo Y, Tully D, Han ES, Yost SE, Yuan Y, Yim JH. Wen W, et al. Among authors: yost se. Cells. 2019 Aug 30;8(9):1010. doi: 10.3390/cells8091010. Cells. 2019. PMID: 31480338 Free PMC article.

7

Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes.

McQuerry JA, Jenkins DF, Yost SE, Zhang Y, Schmolze D, Johnson WE, Yuan Y, Bild AH. McQuerry JA, et al. Among authors: yost se. BMC Cancer. 2019 Sep 5;19(1):881. doi: 10.1186/s12885-019-6052-z. BMC Cancer. 2019. PMID: 31488082 Free PMC article.

8

Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts.

Hutchinson KE, Yost SE, Chang CW, Johnson RM, Carr AR, McAdam PR, Halligan DL, Chang CC, Schmolze D, Liang J, Yuan Y. Hutchinson KE, et al. Among authors: yost se. Clin Cancer Res. 2020 Feb 1;26(3):657-668. doi: 10.1158/1078-0432.CCR-19-1773. Epub 2019 Oct 14. Clin Cancer Res. 2020. PMID: 31611282 Free PMC article.

9

Mutation and immune profiling of metaplastic breast cancer: Correlation with survival.

Afkhami M, Schmolze D, Yost SE, Frankel PH, Dagis A, Amanam IU, Telatar M, Nguyen K, Yu KW, Luu T, Pillai R, Aoun PA, Mortimer J, Yuan Y. Afkhami M, et al. Among authors: yost se. PLoS One. 2019 Nov 6;14(11):e0224726. doi: 10.1371/journal.pone.0224726. eCollection 2019. PLoS One. 2019. PMID: 31693690 Free PMC article.

10

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer.

Lee JS, Yost SE, Blanchard S, Schmolze D, Yin HH, Pillai R, Robinson K, Tang A, Martinez N, Portnow J, Wen W, Yim JH, Brauer HA, Ren Y, Luu T, Mortimer J, Yuan Y. Lee JS, et al. Among authors: yost se. Breast Cancer Res. 2019 Nov 8;21(1):119. doi: 10.1186/s13058-019-1202-4. Breast Cancer Res. 2019. PMID: 31703728 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

71 results

Search Page

Filters